RT Journal Article
SR Electronic
T1 Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials
JF British Journal of Sports Medicine
JO Br J Sports Med
FD BMJ Publishing Group Ltd and British Association of Sport and Exercise Medicine
SP 1161
OP 1169
DO 10.1136/bjsports-2020-103671
VO 55
IS 20
A1 Tom GH Wiggers
A1 Marinus Winters
A1 Noortje AC Van den Boom
A1 Hidde J Haisma
A1 Maarten H Moen
YR 2021
UL http://bjsm.bmj.com/content/55/20/1161.abstract
AB Objective Stem cell therapy is increasingly used for knee osteoarthritis (KOA). We aimed to review the evidence of autologous mesenchymal stem cell therapy on pain, function and severity on imaging in KOA.Design Systematic review of randomised controlled trials (RCTs).Eligibility criteria RCTs evaluating autologous mesenchymal stem cell (MSC) therapy on patient-reported outcome measures and disease severity.Data sources Seven databases were searched until 31 December 2020.Risk of bias and data synthesis Risk of bias was assessed using the ROB V.2. We used Grading of Recommendations Assessment, Development and Evaluation to appraise the certainty of the evidence. Data were synthesised descriptively.Results Fourteen RCTs were included. A total of 408 patients with KOA received MSC therapy derived from bone marrow, adipose tissue or activated peripheral blood. After 1 year, 19 of 26 (73%) clinical outcome measures improved with MSCs compared with control. In the MSC group, patients improved by 1.8–4.4 points on the Visual Analogue Scale (0–10) and 18–32 points of the Knee Osteoarthritis Outcome Score (0–100). Four studies showed better disease severity on imaging after MSC compared with control at 1 year. Ten of 14 (71%) RCTs were at high risk of bias on all outcomes. No serious adverse events were reported after MSC therapy during a maximum of 4 years follow-up.Conclusion We found a positive effect of autologous MSC therapy compared with control treatments on patient-reported outcome measures, and disease severity. The certainty of this evidence was low to very low.PROSPERO registration number CRD42019120506